The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.
September 14th 2024
Tumor infiltrating lymphocytes may have prognostic utility for OS outcomes with adjuvant chemotherapy and trastuzumab in early HER2-positive breast cancer.
Homing in on HER2-Targeted Treatment Strategies in Early and Advanced Breast Cancer
January 5th 2021Clinical risk continues to guide treatment decisions in early-stage HER2-positive breast cancer. The presence of brain metastases has become a driving force for treatment selection in the metastatic setting.
Fixed-Dose Pertuzumab/Trastuzumab Combo Approved in Europe for HER2+ Breast Cancer
December 23, 2020 - The European Commission has approved the fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, to be administered via a subcutaneous injection in the treatment of patients with early and metastatic HER2-positive breast cancer.
Dr. Rao on Emerging Treatments in HER2+ Metastatic Breast Cancer
Ruta D. Rao, MD, associate professor in the Department of Medicine, Division of Hematology at Rush Medical College, as well as the director of the Coleman Foundation Comprehensive Breast Cancer Clinic and medical director of Rush University Cancer Center, discusses emerging treatments for patients with HER2-positive metastatic breast cancer.
FDA Approves Margetuximab-cmkb Plus Chemo in Pretreated Metastatic HER2+ Breast Cancer
December 16, 2020 - The FDA has approved margetuximab-cmkb plus chemotherapy for use in adult patients with metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2 regimens, at least one of which was for metastatic disease.
Trastuzumab Deruxtecan Approaches EU Approval for HER2+ Metastatic Breast Cancer
December 15, 2020 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for fam-trastuzumab deruxtecan-nxki for use as a single agent in adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received 2 or more anti-HER2–based regimens.
Neratinib Improves PFS in HER2+ Breast Cancer With Brain Metastases
December 14, 2020 - The combination of neratinib and capecitabine showed a 34% reduction in the risk of disease progression or death compared with lapatinib and capecitabine in patients with HER2-positive breast cancer who had central nervous system metastases at baseline.
EU Panel Recommends Tucatinib for Locally Advanced or Metastatic HER2+ Breast Cancer
December 11, 2020 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to tucatinib in combination with trastuzumab and capecitabine for use in adult patients with HER2-positive, locally advanced or metastatic breast cancer who had received at least 2 previous anti-HER2 therapies.
AI-Based Analysis Enhances Prediction of Best Responders for Trastuzumab Deruxtecan
December 11th 2020December 11, 2020 - Use of a novel HER2 quantitative continuous score was better able to provide an objective and quantitative assessment of HER2 expression to identify patients who are most likely to respond to fam-trastuzumab deruxtecan-nxki.
Fixed-Dose Pertuzumab/Trastuzumab Combo Nears EU Approval for HER2+ Breast Cancer
November 15, 2020 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the fixed-dose combination of pertuzumab plus trastuzumab with hyaluronidase-zzxf for administration via subcutaneous injection in combination with intravenous chemotherapy in the treatment of patients with early and metastatic HER2-positive breast cancer
Tan Speaks to Benefits of Fixed-Dose Pertuzumab/Trastuzumab Combo in HER2+ Breast Cancer
October 30th 2020Antoinette R. Tan, MD, discusses the FDA approval of the fixed-dose combination of SC pertuzumab and trastuzumab with hyaluronidase, in combination with IV chemotherapy in HER2-positive breast cancer.
Practicing Oncologists Debate New Tactics for Brain Metastases in HER2+ Breast Cancer
October 21st 2020New approaches for treating patients with HER2-positive metastatic breast cancer are showing signs of efficacy against brain metastases, generating excitement about the potential to make critical advances and sparking questions about optimal sequencing.